Abstract
Cervical cancer is a preventable gynecologic malignancy ranking the fourth most common cancer among women in the world. The association between human papillomavirus (HPV) infection and cervical cancer is proven via the identification of high-risk HPV genotypes in more than 95% of cervical cancer specimens. Persistent high-risk HPV infection is the main risk factor for cervical cancer onset and progression, whereas other factors presumably influence the risk of HPV infection acquisition. While the mechanism associated with HPV-independent cervical cancers is unclear, the pathogenesis of HPV-associated cervical lesions and cancer is well-described. Many host, viral, and environmental factors are involved in the pathogenesis of cervical cancer. For more clarity, the pathogenesis of HPV-related cervical cancer can be presented describing changes on the molecular level, cellular level, and tissue level. As the global incidence of cervical cancer continues to rise, the World Health Organization (WHO) announced and stated the implementation of a cervical cancer elimination plan. According to the WHO initiative, HPV vaccination, cervical cancer screening, and treatment of premalignant cervical lesions have to be reinforced. In the absence of HPV-specific medications, clinical specialists and researchers use various medications to manage HPV infection and related lesions. These are imiquimod, cidofovir, anti-VEGF antibodies, recombinant human IFN α−2b, photodynamic therapy, etc. Moreover, multiple studies are investigating the clinical efficacy of therapeutic HPV vaccines. Diagnosis of cervical cancer is guided by the cancer staging classifications/systems, and management of cervical cancer is directed by international guidelines.
This is a preview of subscription content, log in via an institution to check access.
References
Aghbash PS, Hemmat N, Fathi H, Baghi HB (2022) Monoclonal antibodies in cervical malignancy-related HPV. Front Oncol 12:904790. https://doi.org/10.3389/fonc.2022.904790
Aimagambetova G, Azizan A (2018) Epidemiology of HPV infection and HPV-related cancers in Kazakhstan: a review. Asian Pac J Cancer Prev 19(5):1175–1180. Published 2018 May 26. https://doi.org/10.22034/APJCP.2018.19.5.1175
Aimagambetova G, Chan CK, Ukybassova T et al (2021a) Cervical cancer screening and prevention in Kazakhstan and Central Asia. J Med Screen 28(1):48–50. https://doi.org/10.1177/0969141320902482
Aimagambetova G, Babi A, Issanov A et al (2021b) The distribution and prevalence of high-risk HPV genotypes other than HPV-16 and HPV-18 among women attending gynecologists’ offices in Kazakhstan. Biology (Basel) 10(8):794. Published 2021 Aug 18. https://doi.org/10.3390/biology10080794
Aimagambetova G, Babi A, Issa T, Issanov A (2022) What factors are associated with attitudes towards HPV vaccination among Kazakhstani women? Exploratory analysis of cross-sectional survey data. Vaccines (Basel) 10(5):824. Published 2022 May 23. https://doi.org/10.3390/vaccines10050824
Akhatova A, Chan CK, Azizan A, Aimagambetova G (2021) The efficacy of therapeutic DNA vaccines expressing the human papillomavirus E6 and E7 oncoproteins for treatment of cervical cancer: systematic review. Vaccines (Basel) 10(1):53. Published 2021 Dec 31. https://doi.org/10.3390/vaccines10010053
Akhatova A, Azizan A, Atageldiyeva K, Ashimkhanova A, Marat A, Iztleuov Y, Suleimenova A, Shamkeeva S, Aimagambetova G (2022) Prophylactic human papillomavirus vaccination: from the origin to the current state. Vaccines 10(11):1912. https://doi.org/10.3390/vaccines10111912
Amaral E, Cain JM, Hearing F, Lumsden MA, FIGO Committee on Womens Cancer, FIGO Committee on Infections During Pregnancy, FIGO Committee on Well Woman Health Care and FIGO Committee on Ethical Aspects of Human Reproduction and Womens Health (2023) FIGO guidance for sustainable implementation of vaccination programs for women: pregnancy and HPV. Int J Gynaecol Obstet 162(Suppl 1):3–23. https://doi.org/10.1002/ijgo.14894
American College of Obstetricians and Gynecologists (2023) Updated cervical cancer screening guidelines. Available at https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines. Last accessed on 20 Sept 2023
Amin MB, Greene FL, Edge SB et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99. https://doi.org/10.3322/caac.21388
Anastasiou E, McCarthy KJ, Gollub EL, Ralph L, van de Wijgert JHHM, Jones HE (2022) The relationship between hormonal contraception and cervical dysplasia/cancer controlling for human papillomavirus infection: a systematic review. Contraception 107:1–9. https://doi.org/10.1016/j.contraception.2021.10.018
Araldi RP, Sant’Ana TA, Módolo DG et al (2018) The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother 106:1537–1556. https://doi.org/10.1016/j.biopha.2018.06.149
Arbyn M, Xu L (2018) Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines 17:1085–1091. https://doi.org/10.1080/14760584.2018.1548282
Arbyn M, Weiderpass E, Bruni L et al (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis [published correction appears in Lancet Glob Health. 2022 Jan;10(1):e41]. Lancet Glob Health 8(2):e191–e203. https://doi.org/10.1016/S2214-109X(19)30482-6
Arcia Franchini AP, Iskander B, Anwer F et al (2022) The role of chlamydia trachomatis in the pathogenesis of cervical cancer [published correction appears in Cureus. 2022 Mar 3;14(3):c57]. Cureus 14(1):e21331. Published 2022 Jan 17. https://doi.org/10.7759/cureus.21331
Asiaf A et al (2014) Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur J Cancer Prev 23(3):206–224. https://doi.org/10.1097/CEJ.0b013e328364f273
Asthana S, Busa V, Labani S (2020) Oral contraceptives use and risk of cervical cancer – a systematic review & meta-analysis. Eur J Obstet Gynecol Reprod Biol 247:163–175. https://doi.org/10.1016/j.ejogrb.2020.02.014
Babi A, Issa T, Issanov A et al (2021) Prevalence of high-risk human papillomavirus infection among Kazakhstani women attending gynecological outpatient clinics. Int J Infect Dis 109:8–16. https://doi.org/10.1016/j.ijid.2021.06.006
Baik S, Mehta FF, Unsal E, Park Y, Chung SH (2022) Estrogen inhibits epithelial progesterone receptor-dependent progestin therapy efficacy in a mouse model of cervical cancer. Am J Pathol 192(2):353–360. https://doi.org/10.1016/j.ajpath.2021.10.008
Balasubramaniam SD, Balakrishnan V, Oon CE, Kaur G (2019) Key molecular events in cervical cancer development. Medicina (Kaunas) 55(7):384. Published 2019 Jul 17. https://doi.org/10.3390/medicina55070384
Basu P, Taghavi K, Hu SY, Mogri S, Joshi S (2018) Management of cervical premalignant lesions. Curr Probl Cancer 42(2):129–136. https://doi.org/10.1016/j.currproblcancer.2018.01.010
Beal MW (1990) Cervical cytology. NAACOGS Clin Issu Perinat Womens Health Nurs 1(4):470–478
Bhatla N, Singhal S (2020) Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol [Internet] 65:98–108. Available from: https://doi.org/10.1016/j.bpobgyn.2020.02.008
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R (2018) Cancer of the cervix uteri. Int J Gynaecol Obstet 143(Suppl 2):22–36. https://doi.org/10.1002/ijgo.12611
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R (2021) Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet 155(Suppl 1):28–44. https://doi.org/10.1002/ijgo.13865
Bhattacharjee R, Das SS, Biswal SS et al (2022) Mechanistic role of HPV-associated early proteins in cervical cancer: molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol 174:103675. https://doi.org/10.1016/j.critrevonc.2022.103675
Bhuvanendran Pillai A, Mun Wong C, Dalila Inche Zainal Abidin N et al (2022) Chlamydia infection as a risk factor for cervical cancer: a systematic review and meta-analysis. Iran J Public Health 51(3):508–517. https://doi.org/10.18502/ijph.v51i3.8926
Bonde JH, Sandri MT, Gary DS, Andrews JC (2020) Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review. J Low Genit Tract Dis 24(1):1–13. https://doi.org/10.1097/LGT.0000000000000494
Bosch FX, Muñoz N, de Sanjosé S et al (1992) Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 52(5):750–758. https://doi.org/10.1002/ijc.2910520514
Bossens M, Jost M, Van Pachterbeke C et al (2018) Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: a phase 1 investigation. Int J Clin Pharmacol Ther 56(3):134–141. https://doi.org/10.5414/CP203126
Bowden SJ, Bodinier B, Kalliala I et al (2021) Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study. Lancet Oncol 22(4):548–557. https://doi.org/10.1016/S1470-2045(21)00028-0
Brevik TB, da Matta Calegari LR, Metcalfe IM et al (2023) Training health care providers to administer VIA as a screening test for cervical cancer: a systematic review of essential training components. BMC Med Educ 23(1):712. https://doi.org/10.1186/s12909-023-04711-5
Brianti P, De Flammineis E, Mercuri SR (2017) Review of HPV-related diseases and cancers. New Microbiol 40(2):80–85
Brotherton JM (2019) Impact of HPV vaccination: achievements and future challenges. Papillomavirus Res 7:138–140. https://doi.org/10.1016/j.pvr.2019.04.004
Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, Afsar OZ, LaMontagne DS, Mosina L, Contreras M, Velandia-González M, Pastore R, Gacic-Dobo M, Bloem P (2021) HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med 144:106399. https://doi.org/10.1016/j.ypmed.2020.10639955
Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) (2023) Human papillomavirus and related diseases in the world. Summary report 10 Mar 2023. Accessed 5 Sept 2023
Buckley CH, Butler EB, Fox H (1982) Cervical intraepithelial neoplasia. J Clin Pathol 35(1):1–13. https://doi.org/10.1136/jcp.35.1.1
Buskwofie A, David-West G, Clare CA (2020) A review of cervical cancer: incidence and disparities. J Natl Med Assoc 112(2):229–232. https://doi.org/10.1016/j.jnma.2020.03.002
Canavan TP, Doshi NR (2000) Cervical cancer. Am Fam Physician 61(5):1369–1376
Cancer Council (2023) Cervical cancer guidelines. https://www.cancer.org.au/health-professionals/clinical-practice-guidelines/cervical-cancer. Accessed 12 Sept 2023
Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Services (2017) Integrated genomic and molecular characterization of cervical cancer. Nature 543(7645):378–384. https://doi.org/10.1038/nature21386
Canfell K (2019) Towards the global elimination of cervical cancer. Papillomavirus Res 8:100170. https://doi.org/10.1016/j.pvr.2019.100170
Castle PE, Schiffman M, Wheeler CM, Solomon D (2009) Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 113(1):18–25. https://doi.org/10.1097/AOG.0b013e31818f5008
Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II (2018) Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res 5:46–58. https://doi.org/10.1016/j.pvr.2017.12.006
Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A (2019) Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives. J Oncol 2019:3257939. https://doi.org/10.1155/2019/3257939
Chen J, Domingue JC, Sears CL (2017) Microbiota dysbiosis in select human cancers: evidence of association and causality. Semin Immunol 32:25–34. https://doi.org/10.1016/j.smim.2017.08.001
Chino J, Annunziata CM, Beriwal S et al (2020) The ASTRO clinical practice guidelines in cervical cancer: optimizing radiation therapy for improved outcomes. Gynecol Oncol 159(3):607–610. https://doi.org/10.1016/j.ygyno.2020.09.015
Choi S, Ismail A, Pappas-Gogos G, Boussios S (2023) HPV and cervical cancer: a review of epidemiology and screening uptake in the UK. Pathogens 12(2):298. https://doi.org/10.3390/pathogens12020298
Cibula D, Raspollini MR, Planchamp F et al (2023) ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer – update 2023. Int J Gynecol Cancer 33(5):649–666. https://doi.org/10.1136/ijgc-2023-004429
Cohen AC, Roane BM, Leath CA III (2020) Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy. Drugs 80(3):217–227. PMID: 31939072; PMCID: PMC7033025. https://doi.org/10.1007/s40265-019-01249-z
Curty G, de Carvalho PS, Soares MA (2019) The role of the cervicovaginal microbiome on the genesis and as a biomarker of premalignant cervical intraepithelial neoplasia and invasive cervical cancer. Int J Mol Sci 21(1):222. https://doi.org/10.3390/ijms21010222
Daayana S, Elkord E, Winters U et al (2010) Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 102(7):1129–1136. https://doi.org/10.1038/sj.bjc.6605611
de Abreu AL, Malaguti N, Souza RP et al (2016) Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co-infections on the risk of high-grade squamous intraepithelial cervical lesion. Am J Cancer Res 6(6):1371–1383
De Pauw H, Donders G, Weyers S, De Sutter P, Doyen J, Tjalma WAA, Vanden Broeck D, Peeters E, Van Keer S, Vorsters A, Arbyn M (2021) Cervical cancer screening using HPV tests on self-samples: attitudes and preferences of women participating in the VALHUDES study. Arch Public Health = Archives belges de sante publique 79(1):155. https://doi.org/10.1186/s13690-021-00667-4
De Schutter T, Andrei G, Topalis D, Naesens L, Snoeck R (2013) Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med Genet 6:18. https://doi.org/10.1186/1755-8794-6-18
de Villiers EM (2013) Cross-roads in the classification of papillomaviruses. Virology 445(1–2):2–10
Desravines N, Miele K, Carlson R, Chibwesha C, Rahangdale L (2020) Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2–3: a narrative review. Gynecol Oncol Rep 33:100608. https://doi.org/10.1016/j.gore.2020.100608
Desravines N, Hsu CH, Mohnot S et al (2023) Feasibility of 5-fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2/3 [published online ahead of print, 2023 Jul 11]. Int J Gynaecol Obstet 163(3):862–867. https://doi.org/10.1002/ijgo.14983
Di Renzo GC, Giardina I, Clerici G, Brillo E, Gerli S (2016) Progesterone in normal and pathological pregnancy. Horm Mol Biol Clin Investig 27(1):35–48. https://doi.org/10.1515/hmbci-2016-0038
Ding W, Li X, Ji B, Wang Z (2021) Functions of traditional Chinese medicine combined with recombinant human interferon α2b in cervical intraepithelial neoplasias patients. Evid Based Complement Alternat Med 2021:6881720. https://doi.org/10.1155/2021/6881720
Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I (2015) Human papillomavirus molecular biology and disease association. Rev Med Virol 25(Suppl 1):2–23. https://doi.org/10.1002/rmv.1822
Drolet M, Bénard É, Boily M-C, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JML, Cummings T et al (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15:565–580. https://doi.org/10.1016/s1473-3099(14)71073-4
Ellingson MK, Sheikha H, Nyhan K, Oliveira CR, Niccolai LM (2023) Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review. Hum Vaccin Immunother 19(2):2239085. https://doi.org/10.1080/21645515.2023.2239085
Enerly E, Bonde J, Schee K, Pedersen H, Lönnberg S, Nygård M (2016) Self-sampling for human papillomavirus testing among non-attenders increases attendance to the Norwegian cervical cancer screening programme. PLoS One 11(4):e0151978. https://doi.org/10.1371/journal.pone.0151978
Ertik FC, Kampers J, Hülse F, Stolte C, Böhmer G, Hillemanns P, Jentschke M (2021) CoCoss-trial: concurrent comparison of self-sampling devices for HPV-detection. Int J Environ Res Public Health 18(19):10388. https://doi.org/10.3390/ijerph181910388
Fazlollahpour-Naghibi A, Bagheri K, Almukhtar M et al (2023) Trichomonas vaginalis infection and risk of cervical neoplasia: a systematic review and meta-analysis. PLoS One 18(7):e0288443. https://doi.org/10.1371/journal.pone.0288443
Fenner F, Bachmann PA, Gibbs EPJ, Murphy FA, Studdert MJ, White DO (1987) Classification and nomenclature of viruses. Vet Virol 21–38. https://doi.org/10.1016/B978-0-12-253055-5.50006-2
Fernandes A, Viveros-Carreño D, Hoegl J, Ávila M, Pareja R (2022) Human papillomavirus-independent cervical cancer. Int J Gynecol Cancer 32(1):1–7. https://doi.org/10.1136/ijgc-2021-003014
Ferrall L, Lin KY, Roden RBS, Hung CF, Wu TC (2021) Cervical cancer immunotherapy: facts and hopes. Clin Cancer Res 27(18):4953–4973. https://doi.org/10.1158/1078-0432.CCR-20-2833
Ferrera A, Velema JP, Figueroa M et al (2000) Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol 29(5):817–825. https://doi.org/10.1093/ije/29.5.817
Fonseca BO, Possati-Resende JC, Salcedo MP et al (2021) Topical imiquimod for the treatment of high-grade squamous intraepithelial lesions of the cervix: a randomized controlled trial. Obstet Gynecol 137(6):1043–1053. https://doi.org/10.1097/AOG.0000000000004384
Fracella M, Oliveto G, Sorrentino L et al (2022) Common microbial genital infections and their impact on the innate immune response to HPV in cervical cells. Pathogens 11(11):1361. https://doi.org/10.3390/pathogens11111361
Frank LA, Gazzi RP, Mello PA et al (2020) Anti-HPV nanoemulsified-imiquimod: a new and potent formulation to treat cervical cancer. AAPS PharmSciTech 21(2):54. https://doi.org/10.1208/s12249-019-1558-x
Frąszczak K, Barczyński B, Kondracka A (2022) Does Lactobacillus exert a protective effect on the development of cervical and endometrial cancer in women? Cancers (Basel) 14(19):4909. https://doi.org/10.3390/cancers14194909
Frazer IH (2019) The HPV vaccine story. ACS Pharmacol Transl Sci 2:210–212. https://doi.org/10.1021/acsptsci.9b00032
Frederiksen ME, Njor S, Lynge E, Rebolj M (2015) Psychological effects of diagnosis and treatment of cervical intraepithelial neoplasia: a systematic review. Sex Transm Infect 91(4):248–256. https://doi.org/10.1136/sextrans-2014-051754
Gadducci A, Cosio S, Fruzzetti F (2020) Estro-progestin contraceptives and risk of cervical cancer: a debated issue. Anticancer Res 40(11):5995–6002. https://doi.org/10.21873/anticanres.14620
Ghosh I, Mandal R, Kundu P, Biswas J (2016) Association of genital infections other than human papillomavirus with pre-invasive and invasive cervical neoplasia. J Clin Diagn Res 10(2):XE01–XE06. https://doi.org/10.7860/JCDR/2016/15305.7173
Gilson R, Nugent D, Bennett K et al (2020) Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. Health Technol Assess 24(47):1–86. https://doi.org/10.3310/hta24470
Giuliano AR, Tortolero-Luna G, Ferrer E et al (2008) Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 26 Suppl 10(10):K17–K28. https://doi.org/10.1016/j.vaccine.2008.06.021
Goldie SJ, Kohli M, Grima D et al (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96(8):604–615. https://doi.org/10.1093/jnci/djh104
Gong JM, Shen Y, Shan WW, He YX (2018) The association between MTHFR polymorphism and cervical cancer. Sci Rep 8(1):7244. Published 2018 May 8. https://doi.org/10.1038/s41598-018-25726-9
Gupta S, Kumar P, Das BC (2018) HPV: molecular pathways and targets. Curr Probl Cancer 42(2):161–174. https://doi.org/10.1016/j.currproblcancer.2018.03.003
Hamar B, Teutsch B, Hoffmann E et al (2023) Trichomonas vaginalis infection is associated with increased risk of cervical carcinogenesis: a systematic review and meta-analysis of 470 000 patients [published online ahead of print, 2023 Apr 3]. Int J Gynaecol Obstet 163(1):31–43. https://doi.org/10.1002/ijgo.14763
Harper DM, DeMars LR (2017) HPV caccines—a review of the first decade. Gynecol Oncol 146:196–204. https://doi.org/10.1016/j.ygyno.2017.04.004
Hathaway JK (2012) HPV: diagnosis, prevention, and treatment. Clin Obstet Gynecol 55(3):671–680. https://doi.org/10.1097/GRF.0b013e31825caa36
Haverkos HW (2005) Multifactorial etiology of cervical cancer: a hypothesis. MedGenMed 7(4):57. Published 2005 Nov 30
Henry MR (2003) The Bethesda system 2001: an update of new terminology for gynecologic cytology. Clin Lab Med 23(3):585–603. https://doi.org/10.1016/s0272-2712(03)00053-2
Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F (2018) The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol 26(2):158–168. https://doi.org/10.1016/j.tim.2017.07.007
Hostetler KY, Rought S, Aldern KA, Trahan J, Beadle JR, Corbeil J (2006) Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Mol Cancer Ther 5(1):156–159. https://doi.org/10.1158/1535-7163.MCT-05-0200
Huber B, Wang JW, Roden RBS, Kirnbauer R (2021) RG1-VLP and other L2-based, broad-spectrum HPV vaccine candidates. J Clin Med 10(5):1044. https://doi.org/10.3390/jcm10051044
Hudson EA, Coleman DV, Brown CL (1990) The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. Acta Cytol 34(6):902–903
Hussain AM, Lafta RK (2021) Cancer trends in Iraq 2000–2016. Oman Med J 36(1):e219. Published 2021 Jan 31. https://doi.org/10.5001/omj.2021.18
Ilic I, Babic G, Dimitrijevic A, Sipetic Grujicic S, Ilic M (2023) Psychological distress in women with abnormal pap smear results attending cervical cancer screening. J Low Genit Tract Dis 27(4):343–350. https://doi.org/10.1097/LGT.0000000000000761
Inada NM, Buzzá HH, Leite MFM et al (2019) Long term effectiveness of photodynamic therapy for CIN treatment. Pharmaceuticals (Basel) 12(3):107. Published 2019 Jul 12. https://doi.org/10.3390/ph12030107
Insinga RP et al (2009) Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Inf Dis 9(1):119
Inturrisi F, Aitken CA, Melchers WJG, van den Brule AJC, Molijn A, Hinrichs JWJ, Niesters HGM, Siebers AG, Schuurman R, Heideman DAM, de Kok IMCM, Bekkers RLM, van Kemenade FJ, Berkhof J (2021) Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: an observational study. Lancet Regional Health. Europe 11:100235. https://doi.org/10.1016/j.lanepe.2021.100235
Isaka Y, Hori A, Tanaka R, Ichikawa M (2021) Alleviating psychological distress associated with a positive cervical cancer screening result: a randomized control trial. BMC Womens Health 21(1):64. https://doi.org/10.1186/s12905-021-01207-6
Issa T, Babi A, Azizan A et al (2021) Factors associated with cervical cancer screening behaviour of women attending gynaecological clinics in Kazakhstan: a cross-sectional study. Womens Health (Lond) 17:17455065211004135. https://doi.org/10.1177/17455065211004135
Issanov A, Karim ME, Aimagambetova G, Dummer TJB (2022) Does vaccination protect against human papillomavirus-related cancers? Preliminary findings from the United States National Health and nutrition examination survey (2011–2018). Vaccines (Basel) 10(12):2113. https://doi.org/10.3390/vaccines10122113
Jiang T, Wei D, Sha R et al (2018) Psychological factors and demands for breast and cervical cancer screening. Patient Educ Couns 101(7):1270–1275. https://doi.org/10.1016/j.pec.2018.02.014
Jing Y, Wang T, Chen Z et al (2018) Phylogeny and polymorphism in the long control regions E6, E7, and L1 of HPV Type 56 in women from southwest China. Mol Med Rep 17(5):7131–7141. https://doi.org/10.3892/mmr.2018.8743
Johansen C, Mellemkjaer L, Frisch M, Kjaer SK, Gridley G, Olsen JH (2001) Risk for anogenital cancer and other cancer among women hospitalized with gonorrhea. Acta Obstet Gynecol Scand 80(8):757–761. https://doi.org/10.1034/j.1600-0412.2001.080008757.x
Johnson CA, James D, Marzan A, Armaos M (2019) Cervical cancer: an overview of pathophysiology and management. Semin Oncol Nurs 35(2):166–174. https://doi.org/10.1016/j.soncn.2019.02.003
Kamani M, Akgor U, Gültekin M (2022) Review of the literature on combined oral contraceptives and cancer. Ecancermedicalscience 16:1416. https://doi.org/10.3332/ecancer.2022.1416
Kamiza AB, Kamiza S, Mathew CG (2020) HLA-DRB1 alleles and cervical cancer: a meta-analysis of 36 case-control studies. Cancer Epidemiol 67:101748. https://doi.org/10.1016/j.canep.2020.101748
Kang S, Roh JW, Kim JW (2005) Single nucleotide polymorphism: a new risk factor for endometrial cancer? Future Oncol 1(3):323–330. https://doi.org/10.1517/14796694.1.3.323
Karim S, Souho T, Benlemlih M, Bennani B (2018) Cervical cancer induction enhancement potential of chlamydia trachomatis: a systematic review. Curr Microbiol 75(12):1667–1674. https://doi.org/10.1007/s00284-018-1439-7
Katanga JJ, Rasch V, Manongi R, Pembe AB, Mwaiselage JD, Kjaer SK (2021) Concordance in HPV detection between self-collected and health provider-collected cervicovaginal samples using careHPV in Tanzanian women. JCO Glob Oncol 7:985–991. https://doi.org/10.1200/GO.20.00598
Kaufmann AM, Backsch C, Schneider A, Dürst M (2002) HPV induced cervical carcinogenesis: molecular basis and vaccine development. Zentralbl Gynakol 124(11):511–524. https://doi.org/10.1055/s-2002-39579
Kehoe S, Bhatla N (2021) FIGO cancer report 2021. Int J Gynaecol Obstet 155(Suppl 1):5–6. https://doi.org/10.1002/ijgo.13882
Khumalo PG, Carey M, Mackenzie L, Sanson-Fisher R (2023) Cervical cancer screening promotion in Eswatini: a cross-sectional survey of community health workers’ perceived barriers. Asian Pac J Cancer Prev 24(1):231–237. Published 2023 Jan 1. https://doi.org/10.31557/APJCP.2023.24.1.231
Klein C, Kahesa C, Mwaiselage J, West JT, Wood C, Angeletti PC (2020) How the cervical microbiota contributes to cervical cancer risk in Sub-Saharan Africa. Front Cell Infect Microbiol 10:23. https://doi.org/10.3389/fcimb.2020.00023
Koeneman MM, Kruse AJ, Kooreman LFS et al (2016) TOPical Imiquimod treatment of high-grade cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial. BMC Cancer 16:132. https://doi.org/10.1186/s12885-016-2187-3
Koh WJ, Abu-Rustum NR, Bean S et al (2019) Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 17(1):64–84. https://doi.org/10.6004/jnccn.2019.0001
Kovachev SM (2020) Cervical cancer and vaginal microbiota changes. Arch Microbiol 202(2):323–327. https://doi.org/10.1007/s00203-019-01747-4
Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, Wagner S, Boland J, Schussler J, Lowy DR et al (2020) Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst 112:1038–1046. https://doi.org/10.1093/jnci/djaa011
Kunz KR, Turcotte K, Pawer S et al (2023) Cancer in female firefighters: the clinicobiological, psychological, and social perspectives. Front Public Health 11:1126066. https://doi.org/10.3389/fpubh.2023.1126066
Kurman RJ, Malkasian GD Jr, Sedlis A, Solomon D (1991) From Papanicolaou to Bethesda: the rationale for a new cervical cytologic classification. Obstet Gynecol 77(5):779–782
Kwasniewska A, Postawski K, Gozdzicka-Jozefiak A et al (2011) Estrogen and progesterone receptor expression in HPV-positive and HPV-negative cervical carcinomas. Oncol Rep 26(1):153–160. https://doi.org/10.3892/or.2011.1256
Kyrgiou M, Moscicki AB (2022) Vaginal microbiome and cervical cancer. Semin Cancer Biol 86(Pt 3):189–198. https://doi.org/10.1016/j.semcancer.2022.03.005
Kyrgiou M, Athanasiou A, Arbyn M et al (2022) Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP. Lancet Oncol 23(8):e385–e392. https://doi.org/10.1016/S1470-2045(22)00191-7
Lechner M, Liu J, Masterson L, Fenton TR (2022) HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 19(5):306–327. https://doi.org/10.1038/s41571-022-00603-7
Lehoux M, D’Abramo CM, Archambault J (2009) Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics 12(5–6):268–280. https://doi.org/10.1159/000214918
Leo PJ, Madeleine MM, Wang S (2017) Defining the genetic susceptibility to cervical neoplasia – a genome-wide association study. PLoS Genet 13(8):e1006866
Li CC, Feng TH (2022) Hu Li Za Zhi 69(4):20–26. https://doi.org/10.6224/JN.202208_69(4).04
Li C, Wu M, Wang J et al (2010) A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing, People’s Republic of China. Cancer Epidemiol Biomarkers Prev 19(10):2655–2664. https://doi.org/10.1158/1055-9965.EPI-10-0212
Li Q, Liu L, Gu Z, Li M, Liu C, Wu H (2023) Sense of coherence mediates perceived social support and depressive and anxiety symptoms in cervical cancer patients: a cross-sectional study. BMC Psychiatry 23(1):312. https://doi.org/10.1186/s12888-023-04792-y
Lieu D (1996) The Papanicolaou smear: its value and limitations. J Fam Pract 42(4):391–399
Loopik DL, Bentley HA, Eijgenraam MN, IntHout J, Bekkers RLM, Bentley JR (2021) The natural history of cervical intraepithelial neoplasia grades 1, 2, and 3: a systematic review and meta-analysis. J Low Genit Tract Dis 25(3):221–231. https://doi.org/10.1097/LGT.0000000000000604
Ma R, Yu R, Yuan Y, Ren B, Li Y (2021) Effects of traditional Chinese medicine for vaginal lavage combined with psychological intervention in postoperative patients with cervical cancer. Evid Based Complement Alternat Med 2021:5751795. https://doi.org/10.1155/2021/5751795
Maguire R, Kotronoulas G, Simpson M, Paterson C (2015) A systematic review of the supportive care needs of women living with and beyond cervical cancer. Gynecol Oncol 136(3):478–490. https://doi.org/10.1016/j.ygyno.2014.10.030
Maldonado Alvarado E, Osorio Peralta MO, Moreno Vázquez A et al (2017) Effectiveness of photodynamic therapy in elimination of HPV-16 and HPV-18 associated with CIN I in Mexican women. Photochem Photobiol 93(5):1269–1275. https://doi.org/10.1111/php.12769
Malevolti MC, Lugo A, Scala M et al (2023) Dose-risk relationships between cigarette smoking and cervical cancer: a systematic review and meta-analysis. Eur J Cancer Prev 32(2):171–183. https://doi.org/10.1097/CEJ.0000000000000773
Martin CM, O’Leary JJ (2011) Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol 25(5):605–615. https://doi.org/10.1016/j.bpobgyn.2011.04.005
Martins BCT, Guimarães RA, Alves RRF, Saddi VA (2023) Bacterial vaginosis and cervical human papillomavirus infection in young and adult women: a systematic review and meta-analysis. Rev Saude Publica 56:113. Published 2023 Jan 6. https://doi.org/10.11606/s1518-8787.2022056004412
McCluggage WG (2021) Progress in the pathological arena of gynecological cancers. Int J Gynaecol Obstet 155(Suppl 1):107–114. https://doi.org/10.1002/ijgo.13871
McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC (2008) Natural history of cervical neoplasiaand risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9(5):425–434. Epub 2008 Apr 11. PMID: 18407790. https://doi.org/10.1016/S1470-2045(08)70103-7
Mello V, Sundstrom RK (2023) Cervical intraepithelial neoplasia. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544371/
Mertens B, Nogueira T, Stranska R, Naesens L, Andrei G, Snoeck R (2016) Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms. Oncotarget 7(30):47302–47318. https://doi.org/10.18632/oncotarget.10100
Michalas SP (2000) The Pap test: George N. Papanicolaou (1883–1962). A screening test for the prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol 90(2):135–138. https://doi.org/10.1016/s0301-2115(00)00260-8
Mohammed Alwan A, Tavakol Afshari J, Afzaljavan F (2022) Significance of the estrogen hormone and single nucleotide polymorphisms in the progression of breast cancer among female. Arch Razi Inst 77(3):943–958. https://doi.org/10.22092/ARI.2022.357629.2077
Morgan CWC (2005) Cervical cancer screening disparities in an ethnically diverse population of women residing in the United States in 1999: a secondary analysis of data from the 1999 behavioral risk factor surveillance system. USF Tampa Graduate Theses and Dissertations. https://digitalcommons.usf.edu/etd/778
Moscicki AB et al (2010) Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 116(6):1373–1380. https://doi.org/10.1097/AOG.0b013e3181fe777f
Mostowska A, Myka M, Lianeri M, Roszak A, Jagodziński PP (2011) Folate and choline metabolism gene variants and development of uterine cervical carcinoma. Clin Biochem 44(8–9):596–600. https://doi.org/10.1016/j.clinbiochem.2011.02.007
Musa J, Achenbach CJ, O’Dwyer LC et al (2017) Effect of cervical cancer education and provider recommendation for screening on screening rates: a systematic review and meta-analysis [published correction appears in PLoS One. 2017 Dec 29;12(12):e0190661]. PLoS One 12(9):e0183924. https://doi.org/10.1371/journal.pone.0183924
Mutombo AB, Simoens C, Tozin R, Bogers J, Van Geertruyden JP, Jacquemyn Y (2019) Efficacy of commercially available biological agents for the topical treatment of cervical intraepithelial neoplasia: a systematic review. Syst Rev 8(1):132. https://doi.org/10.1186/s13643-019-1050-4
Nagy B, Szekeres-Barthó J, Kovács GL et al (2021) Key to life: physiological role and clinical implications of progesterone. Int J Mol Sci 22(20):11039. https://doi.org/10.3390/ijms222011039
Najib FS, Hashemi M, Shiravani Z, Poordast T, Sharifi S, Askary E (2020) Diagnostic accuracy of cervical pap smear and colposcopy in detecting premalignant and malignant lesions of cervix. Indian J Surg Oncol 11(3):453–458. https://doi.org/10.1007/s13193-020-01118-2
National Cancer Institute (2022) Cervical cancer screening—patient version. https://www.cancer.gov/types/cervical/patient/cervical-screening-pdq. 10 June 2022
Nayar R, Wilbur DC (2017) The bethesda system for reporting cervical cytology: a historical perspective. Acta Cytol 61(4–5):359–372. https://doi.org/10.1159/000477556. Epub 2017 Jul 11. PMID: 28693017
Ntuli L, Mtshali A, Mzobe G, Liebenberg LJ, Ngcapu S (2022) Role of immunity and vaginal microbiome in clearance and persistence of human papillomavirus infection. Front Cell Infect Microbiol 12:927131. Published 2022 Jul 7. https://doi.org/10.3389/fcimb.2022.927131
Olawaiye AB, Baker TP, Washington MK, Mutch DG (2021) The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin 71(4):287–298. https://doi.org/10.3322/caac.21663
Pal A, Kundu R (2020) Human Papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol 10:3116. https://doi.org/10.3389/fmicb.2019.03116
Pangarkar MA (2022) The Bethesda System for reporting cervical cytology. Cytojournal 19:28. Published 2022 Apr 30. https://doi.org/10.25259/CMAS_03_07_2021
Papanicolaou G (1928) New cancer diagnosis. Proceedings of the third race betterment conference, pp. 528–534
Papanicolaou G (1954) Atlas of exfoliative cytology. Cambridge Press. The Commonwealth Fund
Park Y, Baik S, Ho C, Lin CY, Chung SH (2021) Progesterone receptor is a haploinsufficient tumor-suppressor gene in cervical cancer. Mol Cancer Res 19(1):42–47. https://doi.org/10.1158/1541-7786.MCR-20-0704
Peng S, Ferrall L, Gaillard S et al (2021) Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody. mBio 12(1):e03224–e03220. https://doi.org/10.1128/mBio.03224-20
Perkins RB, Guido RS, Castle PE et al (2020) 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors [published correction appears in J Low Genit Tract Dis. 2020 Oct;24(4):427]. J Low Genit Tract Dis 24(2):102–131. https://doi.org/10.1097/LGT.0000000000000525
Poli UR, Bidinger PD, Gowrishankar S (2015) Visual inspection with acetic acid (VIA) screening program: 7 years experience in early detection of cervical cancer and pre-cancers in rural South India. Indian J Community Med 40(3):203–207. https://doi.org/10.4103/0970-0218.158873
Porras C, Sampson JN, Herrero R, Gail MH, Cortés B, Hildesheim A, Cyr J, Romero B, Schiller JT, Montero C et al (2022) Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: the Costa Rica ESCUDDO trial. Vaccine 40:76–88. https://doi.org/10.1016/j.vaccine.2021.11.041
Ramachandran B (2017) Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis. Endocr Relat Cancer 24(4):R99–R108. https://doi.org/10.1530/ERC-16-0571
Richart RM (1967) Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol 10:748
Rizzo AE, Feldman S (2018) Update on primary HPV screening for cervical cancer prevention. Curr Probl Cancer [Internet] 42(5):507–520. Available from: https://doi.org/10.1016/j.currproblcancer.2018.06.013
Ronsini C, Solazzo MC, Molitierno R et al (2023) Fertility-sparing treatment for early-stage cervical cancer ≥2 cm: can one still effectively become a mother? A systematic review of fertility outcomes. Ann Surg Oncol 30(9):5587–5596. https://doi.org/10.1245/s10434-023-13542-z
Salib MY, Russell JHB, Stewart VR, Sudderuddin SA, Barwick TD, Rockall AG, Bharwani N (2020) 2018 FIGO staging classification for cervical cancer: added benefits of imaging. Radiographics 40(6):1807–1822. https://doi.org/10.1148/rg.2020200013
Schroer N et al (2011) Molecular pathobiology of human cervical high-grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. Cancer Res 71:87–97
Sechi I, Elvezia CC, Martinelli M et al (2022) Comparison of different self-sampling devices for molecular detection of human papillomavirus (HPV) and other sexually transmitted infections (STIs): a pilot study. Healthcare (Basel) 10(3):459. Published 2022 Feb 28. https://doi.org/10.3390/healthcare10030459
Shao D, Gao W, Cao FL (2016) Brief psychological intervention in patients with cervical cancer: a randomized controlled trial. Health Psychol 35(12):1383–1391. https://doi.org/10.1037/hea0000407
Shi Y, Li L, Hu Z (2013) A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12. Nat Genet 45:918–922
Shi X, Ma L, Hao J, Yan W (2021) Regulatory effects of comprehensive psychological intervention on adverse emotions and immune status of cervical cancer patients during the perioperative period. Am J Transl Res 13(6):6362–6371
Shim H, Park B, Shin HJ et al (2019) Protective association of HLA-DRB1*13:02, HLA-DRB1*04:06, and HLA-DQB1*06:04 alleles with cervical cancer in a Korean population. Hum Immunol 80(2):107–111. https://doi.org/10.1016/j.humimm.2018.10.013
Shin MB, Liu G, Mugo N et al (2021) A framework for cervical cancer elimination in low-and-middle-income countries: a scoping review and roadmap for interventions and research priorities. Front Public Health 9:670032. https://doi.org/10.3389/fpubh.2021.670032
Singh D, Vignat J, Lorenzoni V et al (2023) Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 11(2):e197–e206. https://doi.org/10.1016/S2214-109X(22)00501-0
Skinner SR et al (2016) Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. Int J Cancer 138(10):2428–2438
Smola S (2017) Immunopathogenesis of HPV-associated cancers and prospects for immunotherapy. Viruses 9(9):254. https://doi.org/10.3390/v9090254
Snoeck R (2006) Papillomavirus and treatment. Antivir Res 71:181–191
Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M (2000) Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 60(2):205–209. https://doi.org/10.1002/(sici)1096-9071(200002)60:2<205::aid-jmv16>3.0.co;2-8
Snoeck R, Andrei G, De Clercq E (2001) Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg 63(2):93–122
Son J et al (2014) Requirement of estrogen receptor alpha DNA-binding domain for HPV oncogene-induced cervical carcinogenesis in mice. Carcinogenesis 35:489–496. https://doi.org/10.1093/carcin/bgt350
Stanley M et al (2010) Pathology and epidemiology of HPV infection in females. Gyn Onc 117(2):S5–S10
Su RY, Ho LJ, Yang HY et al (2020) Association between Trichomonas vaginalis infection and cervical lesions: a population-based, nested case-control study in Taiwan. Parasitol Res 119(8):2649–2657. https://doi.org/10.1007/s00436-020-06759-4
Su Y, Zhang Y, Tong Y et al (2022) Effect and rational application of topical photodynamic therapy (PDT) with 5-aminolevulinic acid (5-ALA) for treatment of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia. Photodiagn Photodyn Ther 37:102634. https://doi.org/10.1016/j.pdpdt.2021.102634
Sun Y, Xu J, Zhou H, You L, Zhu Y (2022) Influence of lacidophilin vaginal capsules plus rh-IFN-α2b on efficacy, vaginal microecology, and safety of patients with HPV infection. Evid Based Complement Alternat Med 2022:3632053. https://doi.org/10.1155/2022/3632053
Swailes AL, Hossler CE, Kesterson JP (2019) Pathway to the Papanicolaou smear: the development of cervical cytology in twentieth-century America and implications in the present day. Gynecol Oncol 154(1):3–7. https://doi.org/10.1016/j.ygyno.2019.04.004
Szpringer E, Lutnicki K, Marciniak A (2004) Photodynamic therapy--mechanism and employment. Ann Univ Mariae Curie Sklodowska Med 59(2):498–502
Takeuchi F, Kukimoto I, Li Z (2019) Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection. Hum Mol Genet 28:341–348
Tambouret RH (2013) The evolution of the Papanicolaou smear. Clin Obstet Gynecol 56(1):3–9. https://doi.org/10.1097/GRF.0b013e318282b982
Terzic M, Makhadiyeva D, Bila J et al (2023) Reproductive and obstetric outcomes after fertility-sparing treatments for cervical cancer: current approach and future directions. J Clin Med 12(7):2614. https://doi.org/10.3390/jcm12072614
The Nobel Prize (2023) The Nobel Prize in physiology or medicine 2008. Available online: https://www.nobelprize.org/prizes/medicine/2008/summary/. Accessed 5 Sept 2023
Tong SY, Lee JM, Song ES et al (2010) The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women. Cancer Causes Control 21(1):23–30. https://doi.org/10.1007/s10552-009-9430-z
Tong L, He M, Zou Y, Li Z (2021) Effects of bundled nursing combined with peer support on psychological state and self-efficacy of patients with cervical cancer undergoing chemotherapy. Am J Transl Res 13(9):10649–10655
Tota EJ, Struyf F, Hildesheim A, Gonzalez P, Ryser M, Herrero R, Schussler J, Karkada N, Rodriguez AC, Folschweiller N et al (2021) Efficacy of AS04-adjuvanted vaccine against human papillomavirus (HPV) types 16 and 18 in clearing incident HPV infections: pooled analysis of data from the Costa Rica vaccine trial and the PATRICIA study. J Infect Dis 223:1576–1581. https://doi.org/10.1093/infdis/jiaa561
Tranoulis A, Laios A, Mitsopoulos V, Lutchman-Singh K, Thomakos N (2017) Efficacy of 5% imiquimod for the treatment of vaginal intraepithelial neoplasia – a systematic review of the literature and a meta-analysis. Eur J Obstet Gynecol Reprod Biol 218:129–136. https://doi.org/10.1016/j.ejogrb.2017.09.020
Trutnovsky G, Reich O, Joura EA et al (2022) Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial [published correction appears in Lancet. 2022 Oct 8;400(10359):1194]. Lancet 399(10337):1790–1798. https://doi.org/10.1016/S0140-6736(22)00469-X
Tu S, Zhang H, Yang X et al (2021) Screening of cervical cancer-related hub genes based on comprehensive bioinformatics analysis. Cancer Biomark 32(3):303–315. https://doi.org/10.3233/CBM-203262
Unanyan A, Pivazyan L, Davydova J et al (2021) Efficacy of photodynamic therapy in women with HSIL, LSIL and early stage squamous cervical cancer: a systematic review and meta-analysis. Photodiagn Photodyn Ther 36:102530. https://doi.org/10.1016/j.pdpdt.2021.102530
Vale DB, Cavalcante LA, Andrade LALA, Teixeira JC, Menin TLDR, Zeferino LC (2019) Stage and histology of cervical cancer in women under 25 years old. J Gynecol Oncol 30(4):e55. https://doi.org/10.3802/jgo.2019.30.e55
van de Sande AJM, Koeneman MM, Gerestein CG, Kruse AJ, van Kemenade FJ, van Beekhuizen HJ (2018) TOPical Imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia (TOPIC-2 trial): a study protocol for a randomized controlled trial. BMC Cancer 18(1):655. Published 2018 Jun 15. https://doi.org/10.1186/s12885-018-4510-7
van de Sande AJM, Kengsakul M, Koeneman MM et al (2023) The efficacy of topical imiquimod in high-grade cervical intraepithelial neoplasia: a systematic review and meta-analysis [published online ahead of print, 2023 Jun 23]. Int J Gynaecol Obstet 164(1):66–74. https://doi.org/10.1002/ijgo.14953
Van Pachterbeke C, Bucella D, Rozenberg S et al (2009) Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 115(1):69–74. https://doi.org/10.1016/j.ygyno.2009.06.042
Verbruggen BS, Boon ME, Boon LM (2006) Dysbacteriosis and squamous (pre) neoplasia of immigrants and Dutch women as established in population-based cervical screening. Diagn Cytopathol 34(5):377–381
Waheed DE, Burdier FR, Eklund C et al (2023) An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses – a meeting report. Prev Med Rep 35:102368. https://doi.org/10.1016/j.pmedr.2023.102368
Walch-Ruckheim B et al (2015) Stromal fibroblasts induce CCL20 through IL6/C/EBPβ to support the recruitment of Th17 cells during cervical cancer progression. Cancer Res 75:5248–5259
Wei B, Chen Y, Lu T, Cao W, Tang Z, Yang H (2022) Correlation between vaginal microbiota and different progression stages of cervical cancer. Genet Mol Biol 45(2):e20200450. https://doi.org/10.1590/1678-4685-GMB-2020-0450
Wieland U, Kreuter A, Pfister H (2014) Human papillomavirus and immunosuppression. Curr Probl Dermatol 45:154–165. https://doi.org/10.1159/000357907
Wilailak S, Kengsakul M, Kehoe S (2021) Worldwide initiatives to eliminate cervical cancer. Int J Gynaecol Obstet 155(Suppl 1):102–106. https://doi.org/10.1002/ijgo.13879
Willows K, Selk A, Auclair MH et al (2023) Canadian colposcopy guideline: a risk-based approach to management and surveillance of cervical dysplasia. Curr Oncol 30(6):5738–5768. Published 2023 Jun 13. https://doi.org/10.3390/curroncol30060431
Wilting SM, Steenbergen RDM (2016) Molecular events leading to HPV-induced high grade neoplasia. Papillomavirus Res 2:85–88. https://doi.org/10.1016/j.pvr.2016.04.003
Wolswinkel JT, Eikelder MLGT, Verhoef CG, Zusterzeel PLM (2023) High- or intermediate-risk histologic features in patients with clinical early-stage cervical cancer planned for fertility-sparing surgery: a systematic review. Cancers (Basel) 15(15):3920. https://doi.org/10.3390/cancers15153920
World Health Organization (2020) Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization, Geneva. Available at https://apps.who.int/iris/handle/10665/361138#:~:text=The%20Global%20Strategy%20also%20proposed,again%20by%20the%20age%20of. Accessed 5 Sept 2023
World Health Organization (2023a) Cytopathology of the uterine cervix – digital atlas. Available at https://screening.iarc.fr/atlascyto.php. Accessed 13 Sept 2023
World Health Organization (2023b) Human papillomavirus vaccines safety. Accessed 7 Sept 2023. Available online: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines/safety
World Health Organization (2023c) Screening and treatment of cervical pre-cancer lesions. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer#:~:text=Screening%20should%20start%20from%2030,every%203%20to%205%20years. Accessed 12 Sept 2023
Yang S, Zhao W, Wang H, Wang Y, Li J, Wu X (2018) Trichomonas vaginalis infection-associated risk of cervical cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 228:166–173. https://doi.org/10.1016/j.ejogrb.2018.06.031
Ye J, Zheng L, He Y, Qi X (2023) Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions. MedComm (2020) 4(5):e368. Published 2023 Sep 14. https://doi.org/10.1002/mco2.368
Yi K, Yang L, Lan Z, Xi M (2016) The association between MTHFR polymorphisms and cervical cancer risk: a system review and meta analysis. Arch Gynecol Obstet 294(3):579–588. https://doi.org/10.1007/s00404-016-4037-6
Yoo YA et al (2013) Progesterone signaling inhibits cervical carcinogenesis in mice. Am J Pathol 183(5):1679–1687. https://doi.org/10.1016/j.ajpath.2013.07.026
Young JM, Zine El Abidine A, Gómez-Martinez RA et al (2022) Protamine sulfate is a potent inhibitor of human papillomavirus infection in vitro and in vivo. Antimicrob Agents Chemother 66(1):e0151321. https://doi.org/10.1128/AAC.01513-21
Zhang S, Xu H, Zhang L, Qiao Y (2020) Cervical cancer: epidemiology, risk factors and screening. Chin J Cancer Res 32(6):720–728. https://doi.org/10.21147/j.issn.1000-9604.2020.06.05
Zheng JJ, Miao JR, Wu Q, Yu CX, Mu L, Song JH (2020) Correlation between HPV-negative cervical lesions and cervical microenvironment. Taiwan J Obstet Gynecol 59(6):855–861. https://doi.org/10.1016/j.tjog.2020.08.002
Zhu H, Shen Z, Luo H, Zhang W, Zhu X (2016) Chlamydia trachomatis infection-associated risk of cervical cancer: a meta-analysis. Medicine (Baltimore) 95(13):e3077. https://doi.org/10.1097/MD.0000000000003077
zur Hausen H (1999) Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol 9(6):405–411. https://doi.org/10.1006/scbi.1999.0144
zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2(5):342–350. https://doi.org/10.1038/nrc798
zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384:260–265. https://doi.org/10.1016/j.virol.2008.11.046
Acknowledgments
The authors would like to acknowledge the Nazarbayev University School of Medicine for the support that enabled the completion of this book chapter.
Conflicts of Interest
The authors declare no conflict of interest.
Funding
This study was supported by the Faculty Development Competitive Research Grant Program (Funder Project Reference: 110119FD4528). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. G.A. is a PI of the project.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Aimagambetova, G. et al. (2024). Cervical Cancer Natural History, Diagnosis, and Treatment: From Molecular Events to Clinical Management. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2024_211
Download citation
DOI: https://doi.org/10.1007/16833_2024_211
Published:
Publisher Name: Springer, Cham